Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24187261 | 0.87 | GPR119 (0.52) | GPR119USP30IRAK4AR | |
| SCHEMBL4114299 | 0.85 | NR1H2 (0.57) | GPR119USP30PIK3R1PIK3CA | |
| SCHEMBL4898897 | 0.85 | USP30 (0.46) | GPR119USP30PIK3R1PIK3CA | |
| SCHEMBL4106892 | 0.85 | FPR2 (0.46) | GPR119USP30 | |
| SCHEMBL3940077 | 0.82 | USP30 (0.49) | GPR119USP30JAK2 | |
| SCHEMBL4901336 | 0.80 | GPR119 (0.48) | GPR119 | |
| SCHEMBL4898816 | 0.79 | SFRP1 (0.49) | GPR119USP30 | |
| SCHEMBL5254230 | 0.79 | TP53 (0.53) | GPR119 | |
| SCHEMBL2675691 | 0.79 | NR1H2 (0.52) | GPR119USP30PIK3R1PIK3CA | |
| SCHEMBL2675502 | 0.79 | FPR2 (0.47) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-08-06 | — | — | US | disclosed |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHINSON MEDIPHARMA LIMITED (CN) | 2018-10-30 | — | — | US | disclosed |
| EP-2606051-B1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| EP-2606051-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022045-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022045-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | GPR119 3359/4885USP30 3092/4885JAK2 1/4885 |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | GPR119 3359/4885USP30 3092/4885JAK2 1/4885 |
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | GPR119 3359/4885USP30 3092/4885JAK2 1/4885 |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | GPR119 3359/4885USP30 3092/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.